Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDRX Biodexa Pharmaceuticals	$7.13 +4.9%	$9.14	$5.85 ▼ $163.10	$24.85M	0.98	148,135 shs	23,694 shs
EQ Equillium	$0.50 -10.5%	$0.39	$0.27 ▼ $1.50	$19.75M	1.15	8.33 million shs	533,855 shs
INAB IN8bio	$2.31 +7.4%	$2.42	$1.98 ▼ $22.50	$6.51M	0.01	124,912 shs	158,514 shs
PMN Promis Neurosciences	$0.56 +2.5%	$0.57	$0.38 ▼ $1.59	$17.98M	-0.04	21.55 million shs	600,171 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDRX Biodexa Pharmaceuticals	+4.85%	+6.42%	-18.72%	-49.43%	+712,999,900.00%
EQ Equillium	-10.45%	-30.25%	+46.90%	+25.84%	-32.53%
INAB IN8bio	+7.44%	+9.48%	-7.23%	-51.08%	-89.14%
PMN Promis Neurosciences	+2.53%	-26.42%	+43.84%	+13.64%	-59.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BDRX Biodexa Pharmaceuticals	0.0977 of 5 stars	0.0	2.0	1.6	0.0	0.0
EQ Equillium	2.8391 of 5 stars	3.2	4.0	2.9	1.7	0.6
INAB IN8bio	3.9504 of 5 stars	3.5	5.0	3.9	2.5	1.3
PMN Promis Neurosciences	1.9926 of 5 stars	3.5	2.0	1.9	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDRX Biodexa Pharmaceuticals	0.00	N/A	N/A	N/A
EQ Equillium	2.33	Hold	$3.00	505.82% Upside
INAB IN8bio	3.00	Buy	$180.00	7,692.21% Upside
PMN Promis Neurosciences	3.00	Buy	$4.33	668.32% Upside

Current Analyst Ratings Breakdown

Latest INAB, EQ, PMN, and BDRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2025	PMN Promis Neurosciences	Leede Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
5/12/2025	PMN Promis Neurosciences	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDRX Biodexa Pharmaceuticals	$470K	55.37	N/A	N/A	$2.91 per share	2.45
EQ Equillium	$41.10M	0.43	N/A	N/A	$0.54 per share	0.92
INAB IN8bio	N/A	N/A	N/A	N/A	$6.00 per share	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	$0.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDRX Biodexa Pharmaceuticals	-$7.32M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
EQ Equillium	-$8.07M	-$0.39	N/A	N/A	N/A	-19.62%	-74.34%	-46.75%	8/14/2025 (Estimated)
INAB IN8bio	-$30.44M	-$13.57	N/A	N/A	N/A	N/A	-195.95%	-127.49%	8/14/2025 (Estimated)
PMN Promis Neurosciences	$2.78M	-$0.05	N/A	N/A	N/A	N/A	-186.19%	-98.56%	8/14/2025 (Estimated)

Latest INAB, EQ, PMN, and BDRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	EQ Equillium	-$0.1850	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	INAB IN8bio	-$1.50	-$1.24	+$0.26	-$1.24	N/A	N/A
8/14/2025	Q2 2025	PMN Promis Neurosciences	-$0.22	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	PMN Promis Neurosciences	-$0.14	-$0.21	-$0.07	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDRX Biodexa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A
INAB IN8bio	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDRX Biodexa Pharmaceuticals	0.01	1.75	1.75
EQ Equillium	N/A	2.70	2.70
INAB IN8bio	0.01	4.30	4.30
PMN Promis Neurosciences	N/A	3.36	3.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDRX Biodexa Pharmaceuticals	17.51%
EQ Equillium	27.05%
INAB IN8bio	92.05%
PMN Promis Neurosciences	50.13%

Insider Ownership

Company	Insider Ownership
BDRX Biodexa Pharmaceuticals	0.34%
EQ Equillium	31.60%
INAB IN8bio	15.50%
PMN Promis Neurosciences	6.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDRX Biodexa Pharmaceuticals	20	3.65 million	3.64 million	Not Optionable
EQ Equillium	40	35.72 million	24.43 million	Not Optionable
INAB IN8bio	20	3.03 million	2.56 million	Not Optionable
PMN Promis Neurosciences	5	32.69 million	30.69 million	Not Optionable

INAB, EQ, PMN, and BDRX Headlines

Recent News About These Companies

Promis Neurosciences (PMN) Expected to Announce Quarterly Earnings on Thursday

August 7 at 2:47 AM | americanbankingnews.com

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference

July 29, 2025 | globenewswire.com

ProMIS Neurosciences Announces Private Placement Financing

July 28, 2025 | globenewswire.com

ProMIS Neurosciences Announces Private Placement Financing

July 22, 2025 | globenewswire.com

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

July 21, 2025 | globenewswire.com

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

July 21, 2025 | globenewswire.com

HC Wainwright & Co. Initiates Coverage of ProMIS Neurosciences (PMN) with Buy Recommendation

July 15, 2025 | msn.com

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 17, 2025 | globenewswire.com

ProMIS Neurosciences Inc. Announces Completion of First Cohort in PRECISE-AD Trial for PMN310 in Alzheimer's Disease

May 13, 2025 | nasdaq.com

ProMIS Neurosciences Stock Price, Quotes and Forecasts | NASDAQ:PMN | Benzinga

May 13, 2025 | benzinga.com

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

May 12, 2025 | globenewswire.com

ProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last year

March 31, 2025 | markets.businessinsider.com

ProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

March 31, 2025 | finanznachrichten.de

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

March 31, 2025 | globenewswire.com

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

March 24, 2025 | globenewswire.com

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

March 13, 2025 | globenewswire.com

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

March 11, 2025 | globenewswire.com

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease

February 25, 2025 | markets.businessinsider.com

ProMIS Neurosciences doses first patiets in Phase 1b PRECISE-AD trial

February 25, 2025 | markets.businessinsider.com

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

February 25, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Figma's Wild IPO Ride: Is the Stock's Premium Price Justified?
By Jeffrey Neal Johnson | August 5, 2025
View Figma's Wild IPO Ride: Is the Stock's Premium Price Justified?
Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat?
By Jeffrey Neal Johnson | July 24, 2025
View Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat?
Shield Your Portfolio From Aug. 1 Tariffs With This Low-Vol ETF
By Jordan Chussler | July 15, 2025
View Shield Your Portfolio From Aug. 1 Tariffs With This Low-Vol ETF
Amazon Takes an Equity Stake in IonQ—Any Upside Potential?
By Gabriel Osorio-Mazilli | August 8, 2025
View Amazon Takes an Equity Stake in IonQ—Any Upside Potential?
AES Gains 20% as Private Equity Eyes AI Hyperscale Energy Player
By Leo Miller | July 14, 2025
View AES Gains 20% as Private Equity Eyes AI Hyperscale Energy Player

INAB, EQ, PMN, and BDRX Company Descriptions

Biodexa Pharmaceuticals NASDAQ:BDRX

$7.13 +0.33 (+4.85%)

Closing price 08/8/2025 03:59 PM Eastern

Extended Trading

$7.10 -0.03 (-0.42%)

As of 08/8/2025 07:53 PM Eastern

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Equillium NASDAQ:EQ

$0.50 -0.06 (-10.45%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$0.49 -0.01 (-1.45%)

As of 08/8/2025 07:59 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

IN8bio NASDAQ:INAB

$2.31 +0.16 (+7.44%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$2.26 -0.06 (-2.38%)

As of 08/8/2025 07:56 PM Eastern

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Promis Neurosciences NASDAQ:PMN

$0.56 +0.01 (+2.53%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$0.57 +0.01 (+1.24%)

As of 08/8/2025 07:55 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time